Latest Insider Transactions at Precision Biosciences Inc (DTIL)
This section provides a real-time view of insider transactions for Precision Biosciences Inc (DTIL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PRECISION BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PRECISION BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.6%
|
$10,000
$1.18 P/Share
|
|
Jun 15
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,858
-2.5%
|
$31,438
$11.2 P/Share
|
|
Jun 15
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,858
+2.44%
|
$2,858
$1.18 P/Share
|
|
Jun 11
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-21.2%
|
$330,000
$11.52 P/Share
|
|
Jun 11
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+17.49%
|
$30,000
$1.18 P/Share
|
|
May 17
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.49%
|
$180,000
$9.38 P/Share
|
|
May 14
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,673
-0.24%
|
$87,057
$9.17 P/Share
|
|
May 14
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
May 13
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,675
-0.48%
|
$77,400
$8.96 P/Share
|
|
May 13
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.05%
|
$0
$0.04 P/Share
|
|
May 13
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,673
-0.24%
|
$87,057
$9.15 P/Share
|
|
May 13
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
May 12
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,676
-0.24%
|
$77,408
$8.72 P/Share
|
|
May 12
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
May 10
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,746
-0.48%
|
$77,968
$8.25 P/Share
|
|
May 10
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.06%
|
$0
$0.04 P/Share
|
|
May 07
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,742
-0.49%
|
$77,936
$8.57 P/Share
|
|
May 07
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.06%
|
$0
$0.04 P/Share
|
|
Apr 21
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,422
+0.67%
|
$13,422
$1.18 P/Share
|
|
Apr 19
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,676
-0.24%
|
$77,408
$8.69 P/Share
|
|
Apr 19
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
Apr 16
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,675
-0.24%
|
$77,400
$8.84 P/Share
|
|
Apr 16
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
Apr 15
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,676
-0.24%
|
$77,408
$8.76 P/Share
|
|
Apr 15
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.53%
|
$0
$0.04 P/Share
|
|
Apr 12
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,741
-0.49%
|
$77,928
$8.67 P/Share
|
|
Apr 12
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.08%
|
$0
$0.04 P/Share
|
|
Apr 09
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,737
-0.5%
|
$77,896
$8.87 P/Share
|
|
Apr 09
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.08%
|
$0
$0.04 P/Share
|
|
Apr 08
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,736
-0.5%
|
$87,624
$9.0 P/Share
|
|
Apr 08
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.09%
|
$0
$0.04 P/Share
|
|
Mar 18
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,665
-0.24%
|
$106,315
$11.08 P/Share
|
|
Mar 18
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 17
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,665
-0.24%
|
$96,650
$10.92 P/Share
|
|
Mar 17
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 16
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,661
-0.24%
|
$106,271
$11.97 P/Share
|
|
Mar 16
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 12
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,712
-0.5%
|
$106,832
$11.36 P/Share
|
|
Mar 12
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.1%
|
$0
$0.04 P/Share
|
|
Mar 11
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,711
-0.5%
|
$106,821
$11.38 P/Share
|
|
Mar 11
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.1%
|
$0
$0.04 P/Share
|
|
Mar 10
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,710
-0.51%
|
$106,810
$11.79 P/Share
|
|
Mar 10
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.11%
|
$0
$0.04 P/Share
|
|
Feb 26
2021
|
Shane Barton VP & Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,294
+50.0%
|
$5,176
$4.61 P/Share
|
|
Feb 26
2021
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,748
+25.62%
|
$10,992
$4.61 P/Share
|
|
Feb 22
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,660
-0.24%
|
$115,920
$12.04 P/Share
|
|
Feb 22
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 19
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,663
-0.25%
|
$106,293
$11.55 P/Share
|
|
Feb 19
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 18
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,705
-0.51%
|
$116,460
$12.23 P/Share
|